Advanced Diagnostics Driving Celiac Disease Market Growth at a 6.7% CAGR

Celiac disease market was valued at $1,419.10 million in 2025 and is projected to reach $2,679.28 million by 2035, growing at a CAGR of 6.7% during the forecast period (2026-2035). The celiac disease market is driven by rising prevalence, greater awareness, and expanded screening. Among these, technological advancements in diagnostics are the key growth driver, as improved serological, genetic, and non-invasive testing enable earlier and more accurate detection, boosting overall market demand.

Browse the full report description of “Celiac Disease Market Size, Share & Trends Analysis Report by Treatment Type (Vitamins and Dietary (Gluten-Free) Supplements, Steroids and Immunosuppressive Drugs, and Therapeutic Vaccines), By Diagnostic Type (Serologic Test, Genetic Testing, and Small-Bowel Biopsy) By End-User (Hospitals and Diagnostics Centers, and Research Institutes), Forecast Period (2026-2035)” of https://www.omrglobal.com/industry-reports/celiac-disease-market

Advanced Diagnostics Accelerating Celiac Disease Detection

Advancements in diagnostic technologies, particularly serological testing, genetic screening, and endoscopic biopsy methods, are significantly shifting the celiac disease landscape from reactive symptom management to proactive, high-precision detection. Serological tests such as anti-tissue transglutaminase (tTG) and anti-endomysial antibodies (EMA) enable faster, more accurate, and less invasive diagnosis, supporting early disease identification and timely intervention. In parallel, genetic testing for HLA-DQ2 and HLA-DQ8 genes helps identify at-risk individuals even before symptoms appear, improving preventive care and long-term patient management.

Further enhancing diagnostic accuracy, advancements in multiplex immunoassays now allow the simultaneous detection of celiac-specific antibodies along with total IgA levels in a single test, overcoming the challenge of false-negative results in patients with IgA deficiency—a common limitation of earlier diagnostic methods.

Additionally, video capsule endoscopy (VCE) has emerged as an effective alternative for patients unable to tolerate conventional endoscopy. This swallow able “pill camera” offers a non-invasive, patient-friendly way to visualize the entire small intestine, improving disease detection and assessment without the discomfort and risks of traditional procedures.

Together, these innovations are expanding screening, improving diagnostic confidence, and enabling earlier and broader identification of celiac disease, thereby increasing test adoption, diagnostic procedure volumes, and overall demand across the celiac disease market.

Key Development in the Celiac Disease Market

• In September 2024, Barinthus Bio announced the start of its first-in-human Phase 1 AVALON trial investigating VTP-1000, an investigational immunotherapy for adults with celiac disease. The randomized, placebo-controlled clinical trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the therapy, addressing a significant unmet need in celiac disease treatment.

• In May 2025, Teva Pharmaceutical Industries, Ltd. announced that the S. Food and Drug Administration (FDA) granted Fast Track designation to its investigational therapy TEV-53408 for the treatment of adults with celiac disease who are on a gluten-free diet.

• In June 2025, Forte Biosciences, Inc. reported positive results from its Phase Ib clinical trial (FB102-101) evaluating FB102, its lead investigational program for the treatment of celiac disease.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Treatment Type
• Diagnostic Type
• End-Users
• Competitive Landscape – Abbott Laboratories, Immco Diagnostics, Inc., Inova Diagnostics, Inc., Omega Diagnostics Group PLC and Thermo Fisher Scientific Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

 Global Celiac Disease Market Report Segment

By Treatment Type

• Vitamins and Dietary (Gluten-Free) Supplements
• Steroids and Immunosuppressive Drugs
• Therapeutic Vaccines

By Diagnostic Type

• Serologic Test
• Genetic Testing
• Small-Bowel Biopsy

By End-User

• Hospitals and Diagnostics Centers
• Research Institutes

Global Celiac Disease Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/celiac-disease-market